Last reviewed · How we verify
XY0206
XY0206 is a small molecule that targets the SGLT2 receptor.
XY0206 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.
At a glance
| Generic name | XY0206 |
|---|---|
| Sponsor | Shijiazhuang Yiling Pharmaceutical Co. Ltd |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
By inhibiting SGLT2, XY0206 reduces glucose reabsorption in the kidneys, thereby lowering blood glucose levels. This makes it a potential treatment for type 2 diabetes.
Approved indications
- Type 2 diabetes
Common side effects
- Nausea
- Diarrhea
- Vomiting
Key clinical trials
- A Study to Evaluate the Effect of XY0206 on the QTc Interval in Chinese Healthy Participants (PHASE1)
- A Study on the Substance Balance of [14C]XY0206 in Healthy Adult Chinese Men (PHASE1)
- A Study of XY0206 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory AML With FLT3-ITD-Mutation (ALIVE) (PHASE3)
- A Study of XY0206 Tablets in Patients With Relapsed / Refractory Acute Myeloid Leukemia (PHASE1)
- A Study of XY0206 in Subjects With Advanced or Metastatic Solid Tumours (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- XY0206 CI brief — competitive landscape report
- XY0206 updates RSS · CI watch RSS
- Shijiazhuang Yiling Pharmaceutical Co. Ltd portfolio CI